Cipla Announces To Price Generic Version Of Remdesivir For COVID-19 Under Rs 5,000
![](https://healthwire.co/wp-content/uploads/2020/06/Cipla.jpg)
Indian drugmaker Cipla has announced that it will price its generic version of Gilead Sciences Inc’s antiviral drug remdesivir for use in COVID-19 patients at less than Rs 5,000. Cipla…
Share